Antiviral efficacy of a respiratory syncytial virus (RSV) fusion inhibitor in a bovine model of RSV infection

Robert Jordan, Matt Shao, Richard L. Mackman, Michel Perron, Tomas Cihlar, Sandy A. Lewis, Eugene J. Eisenberg, Anne Carey, Robert G. Strickley, Jason W. Chien, Mark L Anderson, Heather A. McEligot, Nicole E. Behrens, Laurel J Gershwin

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and pneumonia in infants. Effective treatment for RSV infection is a significant unmet medical need. While new RSV therapeutics are now in development, there are very few animal models that mimic the pathogenesis of human RSV, making it difficult to evaluate new disease interventions. Experimental infection of Holstein calves with bovine RSV (bRSV) causes a severe respiratory infection that is similar to human RSV infection, providing a relevant model for testing novel therapeutic agents. In this model, viral load is readily detected in nasal secretions by quantitative real-time PCR (qRT-PCR), and cumulative symptom scoring together with histopathology evaluations of infected tissue allow for the assessment of disease severity. The bovine RSV model was used to evaluate the antiviral activity of an RSV fusion inhibitor, GS1, which blocks virus entry by inhibiting the fusion of the viral envelope with the host cell membrane. The efficacy of GS1, a close structural analog of GS-5806 that is being developed to treat RSV infection in humans was evaluated in two randomized, blind, placebo-controlled studies in bRSV-infected calves. Intravenous administration of GS1 at 4 mg/kg of body weight/day for 7 days starting 24 h or 72 h postinoculation provided clear therapeutic benefit by reducing the viral load, disease symptom score, respiration rate, and lung pathology associated with bRSV infection. These data support the use of the bovine RSV model for evaluation of experimental therapeutics for treatment of RSV.

Original languageEnglish (US)
Pages (from-to)4889-4900
Number of pages12
JournalAntimicrobial Agents and Chemotherapy
Volume59
Issue number8
DOIs
StatePublished - Aug 1 2015

Fingerprint

Bovine respiratory syncytial virus
Respiratory Syncytial Virus Infections
Respiratory Syncytial Viruses
Antiviral Agents
Human respiratory syncytial virus
Viral Load
Therapeutics
Virus Internalization
Bronchiolitis
Virus Diseases
Respiratory Rate
Infection
Nose
Respiratory Tract Infections
Intravenous Administration
Real-Time Polymerase Chain Reaction
Pneumonia
Theoretical Models
Animal Models
Placebos

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Antiviral efficacy of a respiratory syncytial virus (RSV) fusion inhibitor in a bovine model of RSV infection. / Jordan, Robert; Shao, Matt; Mackman, Richard L.; Perron, Michel; Cihlar, Tomas; Lewis, Sandy A.; Eisenberg, Eugene J.; Carey, Anne; Strickley, Robert G.; Chien, Jason W.; Anderson, Mark L; McEligot, Heather A.; Behrens, Nicole E.; Gershwin, Laurel J.

In: Antimicrobial Agents and Chemotherapy, Vol. 59, No. 8, 01.08.2015, p. 4889-4900.

Research output: Contribution to journalArticle

Jordan, R, Shao, M, Mackman, RL, Perron, M, Cihlar, T, Lewis, SA, Eisenberg, EJ, Carey, A, Strickley, RG, Chien, JW, Anderson, ML, McEligot, HA, Behrens, NE & Gershwin, LJ 2015, 'Antiviral efficacy of a respiratory syncytial virus (RSV) fusion inhibitor in a bovine model of RSV infection', Antimicrobial Agents and Chemotherapy, vol. 59, no. 8, pp. 4889-4900. https://doi.org/10.1128/AAC.00487-15
Jordan, Robert ; Shao, Matt ; Mackman, Richard L. ; Perron, Michel ; Cihlar, Tomas ; Lewis, Sandy A. ; Eisenberg, Eugene J. ; Carey, Anne ; Strickley, Robert G. ; Chien, Jason W. ; Anderson, Mark L ; McEligot, Heather A. ; Behrens, Nicole E. ; Gershwin, Laurel J. / Antiviral efficacy of a respiratory syncytial virus (RSV) fusion inhibitor in a bovine model of RSV infection. In: Antimicrobial Agents and Chemotherapy. 2015 ; Vol. 59, No. 8. pp. 4889-4900.
@article{d4978cd36efd4ba28223dbae9978c611,
title = "Antiviral efficacy of a respiratory syncytial virus (RSV) fusion inhibitor in a bovine model of RSV infection",
abstract = "Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and pneumonia in infants. Effective treatment for RSV infection is a significant unmet medical need. While new RSV therapeutics are now in development, there are very few animal models that mimic the pathogenesis of human RSV, making it difficult to evaluate new disease interventions. Experimental infection of Holstein calves with bovine RSV (bRSV) causes a severe respiratory infection that is similar to human RSV infection, providing a relevant model for testing novel therapeutic agents. In this model, viral load is readily detected in nasal secretions by quantitative real-time PCR (qRT-PCR), and cumulative symptom scoring together with histopathology evaluations of infected tissue allow for the assessment of disease severity. The bovine RSV model was used to evaluate the antiviral activity of an RSV fusion inhibitor, GS1, which blocks virus entry by inhibiting the fusion of the viral envelope with the host cell membrane. The efficacy of GS1, a close structural analog of GS-5806 that is being developed to treat RSV infection in humans was evaluated in two randomized, blind, placebo-controlled studies in bRSV-infected calves. Intravenous administration of GS1 at 4 mg/kg of body weight/day for 7 days starting 24 h or 72 h postinoculation provided clear therapeutic benefit by reducing the viral load, disease symptom score, respiration rate, and lung pathology associated with bRSV infection. These data support the use of the bovine RSV model for evaluation of experimental therapeutics for treatment of RSV.",
author = "Robert Jordan and Matt Shao and Mackman, {Richard L.} and Michel Perron and Tomas Cihlar and Lewis, {Sandy A.} and Eisenberg, {Eugene J.} and Anne Carey and Strickley, {Robert G.} and Chien, {Jason W.} and Anderson, {Mark L} and McEligot, {Heather A.} and Behrens, {Nicole E.} and Gershwin, {Laurel J}",
year = "2015",
month = "8",
day = "1",
doi = "10.1128/AAC.00487-15",
language = "English (US)",
volume = "59",
pages = "4889--4900",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - Antiviral efficacy of a respiratory syncytial virus (RSV) fusion inhibitor in a bovine model of RSV infection

AU - Jordan, Robert

AU - Shao, Matt

AU - Mackman, Richard L.

AU - Perron, Michel

AU - Cihlar, Tomas

AU - Lewis, Sandy A.

AU - Eisenberg, Eugene J.

AU - Carey, Anne

AU - Strickley, Robert G.

AU - Chien, Jason W.

AU - Anderson, Mark L

AU - McEligot, Heather A.

AU - Behrens, Nicole E.

AU - Gershwin, Laurel J

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and pneumonia in infants. Effective treatment for RSV infection is a significant unmet medical need. While new RSV therapeutics are now in development, there are very few animal models that mimic the pathogenesis of human RSV, making it difficult to evaluate new disease interventions. Experimental infection of Holstein calves with bovine RSV (bRSV) causes a severe respiratory infection that is similar to human RSV infection, providing a relevant model for testing novel therapeutic agents. In this model, viral load is readily detected in nasal secretions by quantitative real-time PCR (qRT-PCR), and cumulative symptom scoring together with histopathology evaluations of infected tissue allow for the assessment of disease severity. The bovine RSV model was used to evaluate the antiviral activity of an RSV fusion inhibitor, GS1, which blocks virus entry by inhibiting the fusion of the viral envelope with the host cell membrane. The efficacy of GS1, a close structural analog of GS-5806 that is being developed to treat RSV infection in humans was evaluated in two randomized, blind, placebo-controlled studies in bRSV-infected calves. Intravenous administration of GS1 at 4 mg/kg of body weight/day for 7 days starting 24 h or 72 h postinoculation provided clear therapeutic benefit by reducing the viral load, disease symptom score, respiration rate, and lung pathology associated with bRSV infection. These data support the use of the bovine RSV model for evaluation of experimental therapeutics for treatment of RSV.

AB - Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and pneumonia in infants. Effective treatment for RSV infection is a significant unmet medical need. While new RSV therapeutics are now in development, there are very few animal models that mimic the pathogenesis of human RSV, making it difficult to evaluate new disease interventions. Experimental infection of Holstein calves with bovine RSV (bRSV) causes a severe respiratory infection that is similar to human RSV infection, providing a relevant model for testing novel therapeutic agents. In this model, viral load is readily detected in nasal secretions by quantitative real-time PCR (qRT-PCR), and cumulative symptom scoring together with histopathology evaluations of infected tissue allow for the assessment of disease severity. The bovine RSV model was used to evaluate the antiviral activity of an RSV fusion inhibitor, GS1, which blocks virus entry by inhibiting the fusion of the viral envelope with the host cell membrane. The efficacy of GS1, a close structural analog of GS-5806 that is being developed to treat RSV infection in humans was evaluated in two randomized, blind, placebo-controlled studies in bRSV-infected calves. Intravenous administration of GS1 at 4 mg/kg of body weight/day for 7 days starting 24 h or 72 h postinoculation provided clear therapeutic benefit by reducing the viral load, disease symptom score, respiration rate, and lung pathology associated with bRSV infection. These data support the use of the bovine RSV model for evaluation of experimental therapeutics for treatment of RSV.

UR - http://www.scopus.com/inward/record.url?scp=84939856984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939856984&partnerID=8YFLogxK

U2 - 10.1128/AAC.00487-15

DO - 10.1128/AAC.00487-15

M3 - Article

C2 - 26055364

AN - SCOPUS:84939856984

VL - 59

SP - 4889

EP - 4900

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 8

ER -